Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
A Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.
OpenSEC filings, financial facts, source resources, and Goglides workspace context for CRISPR Therapeutics AG.
OpenRocket Lab reported FY2025 revenue of $601.8 million, Q1 2026 revenue of $200.3 million, a FY2025 net loss of $198.2 million and $1.2 billion of cash. The thesis depends on launch cadence, space systems demand, Neutron investment, operating leverage, cash burn
OpenAlamos Gold is generating record cash flow in a high gold-price environment, but AGI is also asking investors to underwrite a capital-heavy Island Gold District expansion, a 2026 cost decline, hedge cleanup and a path toward materially higher Canadian producti
OpenAeroméxico has premium demand, loyalty scale and record-margin evidence after its U.S. listing, but the Delta JCA, MEX constraints, fuel, FX, engine issues and a negative equity balance sheet make the setup high risk.
OpenTag facets appear after tag usage counts are rebuilt.